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Kyotorphin (KTP, L-tyrosyl-L-arginine) is an endogenous dipeptide initially described to
have analgesic properties. Recently, KTP was suggested to be an endogenous
neuroprotective agent, namely for Alzheimer’s disease (AD). In fact, KTP levels were
shown to be decreased in the cerebrospinal fluid of patients with AD, and recent data
showed that intracerebroventricular (i.c.v.) injection of KTP ameliorates memory
impairments in a sporadic rat model of AD. However, this administration route is far
from being a suitable therapeutic strategy. Here, we evaluated if the blood-brain permeant
KTP-derivative, KTP-NH2, when systemically administered, would be effective in
preventing memory deficits in a sporadic AD animal model and if so, which would be
the synaptic correlates of that action. The sporadic AD model was induced in male Wistar
rats through i.c.v. injection of amyloid b peptide (Ab). Animals were treated for 20 days
with KTP-NH2 (32.3 mg/kg, intraperitoneally (i.p.), starting at day 3 after Ab administration)
before memory testing (Novel object recognition (NOR) and Y-maze (YM) tests). Animals
were then sacrificed, and markers for gliosis were assessed by immunohistochemistry
and Western blot analysis. Synaptic correlates were assessed by evaluating theta-burst
induced long term potentiation (LTP) of field excitatory synaptic potentials (fEPSPs)
recorded from hippocampal slices and cortical spine density analysis. In the absence of
KTP-NH2 treatment, Ab-injected rats had clear memory deficits, as assessed through
NOR or YM tests. Importantly, these memory deficits were absent in Ab-injected rats thatin.org July 2020 | Volume 11 | Article 9851
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Frontiers in Pharmacology | www.frontiershad been treated with KTP-NH2, which scored in memory tests as control (sham i.c.v.
injected) rats. No signs of gliosis could be detected at the end of the treatment in any
group of animals. LTP magnitude was significantly impaired in hippocampal slices that
had been incubated with Ab oligomers (200 nM) in the absence of KTP-NH2. Co-
incubation with KTP-NH2 (50 nM) rescued LTP toward control values. Similarly, Ab
caused a significant decrease in spine density in cortical neuronal cultures, and this
was prevented by co-incubation with KTP-NH2 (50 nM). In conclusion, the present data
demonstrate that i.p. KTP-NH2 treatment counteracts Ab-induced memory impairments
in an AD sporadic model, possibly through the rescuing of synaptic plasticity mechanisms.Keywords: amidated-kyotorphin, Alzheimer’s disease, amyloid b peptide, novel object recognition test, Y-Maze
alternation test, long-term potentiation, memory, synaptic plasticityINTRODUCTION
Kyotorphin (KTP) is an endogenous dipeptide composed by
tyrosine and arginine (L-tyrosyl-L-arginine) residues, first
described as a powerful analgesic molecule (Takagi et al.,
1979a; Takagi et al., 1979b). Given its analgesic properties,
KTP has been investigated as a drug for pain treatment
(Ribeiro et al., 2011b; Santos et al., 2013). Although
mechanisms underpinning KTP-induced analgesic effects are
still not entirely understood, some authors argue that KTP
binds to a specific Gi-coupled protein receptor (KTPr), which
despite numerous efforts, has never been isolated (Ueda et al.,
1989). Nevertheless, it is well-known that KTP triggers the
release of met-enkephalins (met-enk) and b-endorphins in a
naloxone-reversible opioid receptors mediated-mechanism
(Takagi et al., 1979a; Shiomi et al., 1981; Ueda et al., 1982;
Oliveira et al., 2016), an effect antagonized by the dipeptide L-
Leu-L-Arg (a KTPr antagonist) (Ueda et al., 1989; Kawabata
et al., 1992).
Interestingly, despite the high expression of KTP in the cortex,
the levels of enkephalins and of opioid receptors are low,
suggesting other non-opioid physiological actions for KTP
(Ueda et al., 1980). Remarkably, KTP has been pointed as a
possible neuroprotective factor (Dzambazova and Bocheva,
2010), emerging as a novel drug to be explored for Alzheimer´s
disease (AD) and other therapeutic applications.
AD is a chronic progressive neurodegenerative disease and
the most common cause of dementia in elderly. The presence of
senile plaques (amyloid beta (Ab) peptide) and neurofibrillary
tangles (hyperphosphorylated tau (p-Tau) protein) in the brain
are the molecular hallmarks of the disease (Price et al., 1991;
Citron, 2010). AD represents a challenge for drug discovery since
effective neuroprotective treatments are still needed. It was
reported that AD patients present decreased levels of KTP in
cerebrospinal fluid (CSF) (Santos et al., 2013) suggesting the
increase in KTP levels as a possible therapeutic strategy.
Despite the encouraging recent data showing that
intracerebroventricular (i.c.v) injection of KTP ameliorates
memory impairments in a sporadic AD rat model (Angelova
et al., 2019), its weak activity when administered systemicallyin.org 2(Chen et al., 1998) renders KTP as an unrealistic pharmacological
tool to fight AD. Amidated-kyotorphin (KTP-NH2), is a KTP
derivative capable of crossing the blood brain barrier (BBB)
(Ribeiro et al., 2011a; Ribeiro et al., 2011b), and with efficacy to
decrease neuronal damage induced by cerebral hypoperfusion (Sá
Santos et al., 2016). Altogether, these findings prompted us to
investigate whether systemic administration of KTP-NH2 would be
effective to ameliorate memory impairment in an animal model of
sporadic AD, and if so, which are the synaptic mechanisms operated
by KTP-NH2 to protect synapses against Ab-induced toxicity.MATERIALS AND METHODS
Drugs
Amyloid b Peptide
For in vivo experiments, Amyloid b (Ab) peptide 1 to 42 (Ab1–42)
(H-1368, Bachem Bubendorf, Switzerland) was dispersed in
water at a concentration of 2.25 mg/ml.
In order to prepare oligomeric species of Ab1–42 (Abolig), Ab1–42
(1 mg/ml) (A-42-T, GenicBio, Shanghai, China) was suspended in
phosphate-buffered saline (PBS), supplemented with 0.025%
ammonia solution and adjusted to a final pH 7.2 (HCl). Species
separation was based on an ultrafiltration process, as previously
described (Giuffrida et al., 2009). Briefly, Ab1–42 (220 µM) was
allowed to oligomerize by constant shaking at 600 rpm, at 37°C for
16 h and ultracentrifuged (40,000g, 30 min) for separation of fibrils
(pellet). The supernatant was further separated in centrifugal filters
(30 kDa Amicon Ultra). The concentration of the retained fraction,
corresponding to oligomers > 30 kDa, was spectrophotometrically
determined (ϵ280 = 1490 M−1 cm−1). Oligomers aliquots (120–
220 µM) were immediately stored at −80°C until further use.
In addition, in vitro experiments using primary neuronal
cultures were performed using the Ab fragment 25–35 (Ab25–35)
(Bachem, Bubendorf, Switzerland). Ab25–35 represents the
biologically active region of Ab and induces the same
molecular and cellular dysfunction as Ab1–42 species, being this
effect similar to what has been observed in AD brains (Pike et al.,
1995; Kaminsky et al., 2010). Stock solutions of Ab25–35 were
prepared in MilliQ water to a final concentration of 1 mg/ml.July 2020 | Volume 11 | Article 985
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KTP-NH2 peptide was synthesized as previously described
(Ribeiro et al., 2011b). For in vivo experiments, KTP-NH2 was
dissolved in physiological saline solution (0.9% NaCl, vehicle
solution), as a 100 mM stock solution, and it was administered at
a dose of 32.3 mg/kg, at a volume of 1 ml/kg. The selected dose
was based on previous results regarding KTP-NH2 analgesic
action profile (Ribeiro et al., 2011b; Ribeiro et al., 2013). For ex
vivo and in vitro experiments, KTP-NH2 was prepared in




Male Wistar rats (8–10 weeks), purchased from Charles River
Laboratories (Lyon, France), were housed in a group of 2 per
cage and maintained under controlled conditions (20 ± 2°C;
14:10 h light/dark cycle, lights on between 7:00 AM and 9:00 PM).
All animals had unrestricted access to food and water. The
handling of animals and all described procedures were
conducted according to the European Community (86/609/
EEC; 2010/63/EU; 2012/707/EU) and Portuguese (DL 113/
2013) legislation for the protection of animals used for
scientific purposes, and they were approved by the Ethical
Committee for Animal Research of Instituto de Medicina
Molecular João Lobo Antunes (iMM), Faculty of Medicine,
University of Lisbon, and the Portuguese Competent Authority
for Animal Welfare (DGAV) in Portugal.
The animal model of AD was created based on the Ab1–42
i.c.v. injection method, as previously described (Canas et al.,
2009; Zhang et al., 2015). Surgical procedures were performed
when animals reached 230 to 320 g and during the light period.
Briefly, animals were anesthetized with isoflurane (2–3% in O2)
using a RC2 Rodent Anesthesia System (VetEquip Inc.,
California, USA), firstly using a plexiglas chamber and
thereafter maintained via facial mask. EMLA® cream was
applied in the ear canal, and Bupivacaine Hydrochloride 0.25%
(8 mg/kg, SC) was administered at the incision site for local
anesthetics. Lacryvisc® (Carbomer 974P 0.3%) was applied onFrontiers in Pharmacology | www.frontiersin.org 3the eyes to avoid dehydration. Buprenorphine (0.05 mg/kg, SC)
was also administered pre-emptively for general analgesia, so it
would be already in action when animals recovered
from anesthesia.
Twelve animals were i.c.v. injected with Ab peptide (2.25 mg/
ml) in 5 µl and 14 were injected with 5 µl of water (vehicle) at day
zero. Injections were performed with a 33-gauge Hamilton
microsyringe (Hamilton Company, Nevada, USA) using a
microinjection pump (World Precision Instruments, Inc.,
Florida, USA) with a rate of 500 nl/min, in the right lateral
ventricle using a stereotactic system (anteroposterior, −0.84 mm
from bregma; medial/lateral, 1.5 mm; and dorsal/ventral, −3.5
mm). Injections lasted 10 min, and the needle with the syringe
was left in place for 2 min after the injection to ensure complete
infusion of Ab. Animal body temperature was kept constant at
37°C using a heating pad. A timeline of all the experimental
events is depicted in Figure 1A. Previous work reported soluble
forms of Ab on the hippocampus of i.c.v. Ab injected animals
(Canas et al., 2009), thus showing Ab diffusion through this brain
region. Compared with transgenic models of AD, the i.c.v. Ab-
induced sporadic model of AD is more relevant for the study of
Ab-induced pathophysiological traits of AD. Moreover, the
transgenic models of AD are usually used to study the familial
form of the disease, which barely represents 5% of AD cases
(Lecanu and Papadopoulos, 2013).
Chronic Intraperitoneal KTP-NH2
Treatment
Thirteen animals underwent a chronic 18-day treatment
regimen of KTP-NH2 (32.3 mg/kg, single i.p. dose/day),
starting the second day after i.c.v. administration of Ab1–42
(Ab + KTP-NH2 group, n=6) or vehicle (KTP-NH2 group,
n=7), and lasting until sacrifice. The remaining thirteen animals
received the vehicle solution following the same treatment
regimen: Ab + vehicle (Ab group, n = 6) and vehicle +
vehicle (control group, n = 7). The experimental groups of
animals are depicted in Figure 1B. During the last 5 days of i.p.
treatments (KTP-NH2 or vehicle), animals were tested in the
behavioral paradigms identified below. During behavioralA B
FIGURE 1 | Experimental design. (A) Animals were i.c.v. injected with Ab (Ab1–42) or vehicle (water) at day 0. On day 2, KTP-NH2 or vehicle (saline solution) i.p.
administration began, simultaneously with handling. Behavioral tests were performed between days 15 and 20: Y-Maze Spontaneous Alternation test (YM-SAT),
Open Field test (OFT), and Novel Object Recognition test (NORT). On day 21 animals were sacrificed (†) for molecular analyses (WB and IHC). (B) Four experimental
groups were tested: Control (i.c.v. and i.p. vehicle administration, n = 7); Ab (i.c.v. Ab administration and i.p. vehicle treatment, n = 6); KTP-NH2 (i.c.v. vehicle
administration and i.p. KTP-NH2 treatment, n = 7), and Ab + KTP-NH2 (i.c.v. Ab administration and i.p. KTP-NH2 treatment, n = 6).July 2020 | Volume 11 | Article 985
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and before return to the animal house.
Behavioral Testing
Behavioral tests were performed from the fifteenth day after Ab1–
42 injection, following a previously described protocol (Cunha
et al., 2008; Canas et al., 2009). The handling period coincided
with the first 13 days of KTP-NH2 treatment, where animals
were handled for a few minutes before the i.p. injection so that
they became used to the experimenter and to the testing room.
All behavioral tests were carried out between 9:00 AM and 6:00
PM. All the apparatus used were cleaned with 70% ethanol
between animals switching. After placing the animal inside the
behavioral apparatus, the experimenter immediately left the
room. The experimenter conducting behavioral analysis was
blinded to treatment conditions.
Tests were performed in the following order: Y-Maze
Spontaneous Alternation Test (YM-SAT), Open Field Test
(OFT), and Novel Object Recognition Test (NORT) (Figure 1A).
The YM-SATwas performedbefore theNORT to evaluateworking
memory for a less complex paradigm first. Since OFT and NORT
use the same testing arena, the OFT was performed during the first
5minof thefirst dayofNORThabituationperiod (first contactwith
the arena).
Y-Maze Spontaneous Alternation Test (YM-SAT)
The spontaneous alternation version of the Y-Maze test evaluates
spatial working memory by taking advantage of the willingness
of rodents to explore new environments. The testing protocol for
YM-SAT has been described in detail previously (Maurice et al.,
1996). The wood-made maze used was composed of 3 arms (30 x
10 x 20 cm each), converging to an equal angle. Visual cues were
placed on the walls of the maze. Briefly, without prior
habituation, animals were individually placed at the end of one
arm and allowed to freely move through the maze for 8 min. Two
independent investigators visually recorded arm entries, and the
comparison between recordings showed total agreement.
An entry was considered valid when all four limbs of the
animal were within the arm. An alternation was defined as
entries in all three arms on consecutive occasions. The number
of maximum possible alternations for each animal was therefore
the total number of arm entries minus two. The percentage of
spontaneous alternation was calculated as actual alternations/
maximum alternations ×100. In addition, the total number of
arm entries was used as a measure of locomotor activity.
Open Field Test (OFT)
The OFT is widely used to assess individual spontaneous
locomotor activity and anxiety-like behavior when animals are
introduced to a novel environment (Prut and Belzung, 2003;
Bailey and Crawley, 2009; Castanheira et al., 2018). Importantly,
this test allows to detect bias in animal behaviour that could
affect performance on NORT, since locomotor activity can
impact exploratory drive (Broadhurst, 1957; Broadhurst, 1958).
The open field arena consisted of an empty square wood box
(67 x 67 x 51 cm height), virtually divided into three concentric
squares: a peripheral, an intermediate and a central zone. TheFrontiers in Pharmacology | www.frontiersin.org 4testing protocol has been described in detail previously (Gould
et al., 2009). Briefly, animals were individually placed in the
center of the arena and allowed to freely move for 5 min. The
behaviour was video-recorded and analyzed by the tracking
software Smart® (version 2.5; Panlab, Barcelona, Spain). The
reference point used for the animal tracking position was defined
as the center of the animal dorsum. Both total travelled distance
(cm) and average velocity (cm/s) were measured to assess
locomotor activity. In addition, the percentage of time spent in
the arena periphery was used as an indicator of the level of
anxiety-like behavior. All animals were tested only once.
Novel Object Recognition Test (NORT)
Considering that episodic long-term memory is the predominant
cognitive deficit in AD, animals were subjected to the NORT
(Antunes and Biala, 2012). To assess long-term memory a
retention interval (RI) of 24 h was used. This test consists of three
phases: habituation, familiarization (training), and test. The
habituation phase consisted of 3 sessions of habituation to the
arena (15 min each day). During both familiarization and test
phases, two objects were added to the same arena, always in the
same place. The objects used in this test were translucent glass
bottles and brown glass bottles without labels, that were similar in
size and shape, but which the animals were able to discriminate
between them. To prevent coercion to explore the objects, animals
were individually placed in the middle of the opposite wall where
objects were, with their backs to them, and allowed to freely move
for 5 min. In the familiarization phase, animals were presented with
two equal objects, which we herein name as ‘familiar’ objects.
During the familiarization phase, chosen objects were
counterbalanced between animals within the same experimental
group to reduce any object preference effect. Similarly, object
localization was counterbalanced between both arena sides, to
eliminate possible preference confounds for a specific side of the
arena. Following sample-objects exposure, animals returned to the
home cage for 24 h. In the test phase, one of the previously
experienced objects (now considered familiar objects) was
substituted by a new object (considered the novel object).
Exploration was scored when the animal touched an object with
its forepaws or snout, bit, licked, or sniffed the object from a distance
of no more than 1.5 cm. Running around the object or climbing on
it was not recorded as exploration. Animal movements were
recorded using the SMART® video-tracking software (version 2.5;
Panlab, Barcelona, Spain). A post-analysis was conducted to refine
the results obtained by software measures. Two independent
investigators made the post-analysis with a high degree of
concordance between them.
Three indexes were calculated in order to evaluate both
preference between objects and recognition of the novel object:
1) the object preference index, which is the ratio between the
time spent exploring one object over the total time spent
exploring both objects [object 1 or object 2/(object 1 + object
2)], and it is assessed both in the training and test phases; 2) the
object recognition index, which is the ratio between the time
spent exploring the novel object and the total time spent
exploring both objects [novel/(novel + familiar)], and it is
an index of retention, used for analysis of the test phaseJuly 2020 | Volume 11 | Article 985
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which is the ratio between the difference between the time spent
exploring the novel and the familiar object, and the total time
spent exploring both objects [(novel − familiar)/(novel +
familiar)], allowing an easier visualization of data since no
memory retention scores as zero (Antunes and Biala, 2012).
Western Blot
After behavioral tests, three/four animals from each group were
deeply anesthetized with isoflurane (Esteve, Barcelona, Spain)
and decapitated. Their brains were quickly removed and placed
in ice-cold aCSF, continuously oxygenated (O2/CO2: 95%/5%) to
isolate both hippocampi. The left and the right hippocampi were
individually frozen in liquid nitrogen and stored at −80°C. The
two hippocampi were analyzed separately to allow the separate
quantification of the hippocampus of the side of the i.c.v.
injection (right, ipsilateral) and of the contralateral to it. Since
both hippocampi could be differently exposed to Ab, they could
display different degrees of gliosis. Using a Potter homogenizer,
tissue homogenates were prepared from frozen samples by
solubilizing them in Radio-Immunoprecipitation Assay (RIPA)
buffer: 50 mM Tris-base (pH 7.5), 150 mM NaCl, 5 mM
Ethylenediaminetetraacetic Acid (EDTA), 0.1% Sodium
Dodecyl Sulphate (SDS), and 1% Triton X-100, supplemented
with phosphatase inhibitors: 10 nM NaF; 5 mM Na3VO4 and a
protease inhibitor cocktail (Complete Mini-EDTA free from
Roche, Penzberg, Germany). Samples were centrifuged at
13,000g, 4°C for 10 min, and the supernatant was collected and
placed in fresh tubes. Protein concentration was quantified
through Bradford method, using Bio-Rad DC reagent (Bio-Rad
Laboratories, Berkeley, CA, United States). All samples were
prepared with the same amount of total protein (35 µg), by
adding a loading buffer (350 mM Tris-HCl (pH 6.8), 10% SDS,
30% glycerol, 600 mM Dithiothreitol, 0.06% bromophenol blue),
and then boiled at 95°C for 5 min. Next, samples and the
molecular weight marker (PageRuler™ Plus Prestained Protein
Ladder, 10 to 250 kDa, ThermoFisher Scientific, Massachusetts,
USA) were loaded and separated on 12% SDS–polyacrylamide
gel electrophoresis (SDS–PAGE) within a standard migration
buffer (25 mMTris-base (pH 8.3), 192 mMGlycine, 10% SDS), at
a constant voltage between 80 and 120 mV. Subsequently,
proteins were electrotransferred, at 400 mA for 1 h 30 min,
from the gel to a polyvinylidene difluoride (PVDF) membrane
(GE Healthcare, Buckinghamshire, United Kingdom), previously
activated with methanol for 5 min, within the standard buffer (25
mM Tris (pH 8.3), 192 mM Glycine, 15% methanol) for wet
transfer conditions. Afterward, membranes were stained with
Ponceau S solution (Sigma-Aldrich®) to check for transference
efficacy, and blocked with a 3% bovine serum albumin (BSA) in
TBS-T (Tris-Buffered Saline with Tween-20 containing in mM:
Tris base 20; NaCl 137 and 0.1% Tween-20) during 1 h at RT to
avoid non-specific binding. Membranes were incubated with the
primary antibodies overnight at 4°C, and then with the HRP-
conjugated secondary antibodies (1:10000, Santa Cruz
Biotechnology, Dallas, TX, USA) for 1 h at RT, all diluted in
3% BSA solution in TBS-T. The primary antibodies used were
rabbit polyclonal antibody anti-GFAP (1:5000, Sigma, St. Louis,Frontiers in Pharmacology | www.frontiersin.org 5MO, USA), goat polyclonal antibody anti-Iba-1 (1:1000,
Abcam, Cambridge, UK), and mouse monoclonal antibody
anti-GAPDH (1:5000, Invitrogen, Carlsbad, California, USA).
Chemiluminescent detection was performed with ECL Plus
Western Blotting Detection Reagent (GE Healthcare,
Buckinghamshire, UK) in the ChemiDoc™ XRS+ System from
Bio-Rad. The integrated intensity of each band was calculated
using computer-assisted densitometry analysis with Image-J 1.45
software (Bethesda Softworks, Bethesda, MD, United States) and
normalized to the integrated intensity of the loading control
(GAPDH). Images were prepared for printing in Image Lab
software 5.2.1 (software available in ChemiDoc XRS+ system,
Bio-Rad).
Immunohistochemistry
After behavioral tests, three animals of each group were deeply
anesthetized with ketamine/xylazine mixture (120 mg/kg/16 mg/
kg) at a volume of 1 ml/kg. After reaching a deep anesthesia state,
the animals were perfused transcardially with approximately
200 ml of warmed (37°C) 0.9% saline solution, to clear the
blood from the circulatory system, followed by approximately
500 ml of 4% paraformaldehyde (PFA) in phosphate buffer (PBS,
140 mM NaCl, 3 mM KCl, 20 mM Na2HPO4, 1.5 mM KH2PO4,
pH 7.4) (Gage et al., 2012). Animals were then decapitated, and
their brains were carefully removed and maintained for post-
fixation in the same fixative solution at 4°C overnight. After
that, brains were washed twice with PBS, and then cryoprotected
at 4°C by immersion in increasing concentrations of sucrose (15%
and 30%). Subsequently, brains were gelatin-embedded (7.5%
gelatin in 15% sucrose) and then sectioned at a thickness of 12 µm
on a cryostat (LEICA CM 3050S, Wetzlar, Germany), by the
Histology and Comparative Pathology Laboratory of iMM. Only
the coronal sections located at the level of hippocampus (around
−2.92 mm and −5.04 mm from Bregma) were collected, mounted
on SuperFrost® Plus slides (Menzel-Glaser, Braunschweig,
Germany) and stored at −20°C for further use.
For the immunohistochemical analyses, slices were placed in
PBS for 10 min at 37°C to remove the gelatin from brain tissue.
Then, each slice was surrounded with DAKO pen (Dako,
Glostrup, Denmark) to protect staining areas from drying out
and from mixing with each other. After an incubation in glycine
(0.1 M) for 10 min to remove the small toxic aldehydes
originated from PFA degradation, sections were subsequently
treated with 0.1% Triton X-100 in PBS (10 min) for membrane
permeabilization, washed twice (10 min each time) with PBS in
the presence of 0.1% Tween-20 (PBS-T) and then blocked with a
blocking solution (10% Fetal Bovine Serum (FBS), 6/10% BSA in
PBS-T) for 30 min at RT. Next, slices were incubated with the
primary antibodies overnight at 4°C, and with the fluorophores
coupled-secondary antibodies for 2 h at RT in a humidified dark
chamber. The nuclei were stained with Hoechst 33342 (20 mg/ml,
Invitrogen) for 10 min at RT. The slices were mounted in Mowiol
(Sigma). The primary antibodies used were mouse monoclonal
antibody anti-GFAP (1:1000, Mill ipore, Burlington,
Massachusetts, USA), and goat polyclonal antibody anti-Iba1
(1:1000, Abcam). The secondary antibodies were donkey anti-
mouse-Alexa Fluor 568, and donkey anti-goat-Alexa Fluor 488July 2020 | Volume 11 | Article 985
Belo et al. Neuroprotective Action of Amidated-Kyotorphin(1:500, Invitrogen). Images were acquired on an inverted wide
field fluorescence microscope (Zeiss Axiovert 200, Zeiss,
Oberkochen, Germany), using a monochrome digital camera
(AxioCamMR3, Zeiss), with a 40× objective (Zeiss). The software
AxioVision 4.7.1 (Carl Zeiss Imaging Systems) was used for
image acquisition. Immunofluorescence images were acquired in
two areas of the hippocampus: cornu ammonis 1 (CA1) and
dentate gyrus (DG), of both hemispheres of each animal.
Freshly Prepared Hippocampal Slices and
Drug Treatment
Male C57BL/6J mice (8–11 weeks old), purchased to Charles
River Laboratories (Lyon, France), were housed in groups of 4/5
per cage and maintained under controlled conditions (21 ± 1°C;
55 ± 10% humidity; 12:12 h light/dark cycle). Animals were
deeply anesthetized with isoflurane (Esteve, Barcelona, Spain)
and decapitated to quickly remove their brains. Then, brains
were placed in ice-cold artificial cerebral-spinal fluid solution
(aCSF; 124 mM NaCl, 3 mM KCl, 1.2 mM NaH2PO4, 25 mM
NaHCO3, 2 mM CaCl2, 1 mM MgSO4, and 10 mM glucose, pH
7.4), continuously oxygenated (O2/CO2: 95%/5%) to dissect both
hippocampi. Acute hippocampal slices were cut, with a thickness
of 400 µm, perpendicularly to the long axis of the hippocampus
using a McIlwain tissue chopper, and placed in a resting chamber
filled with continuously oxygenated aCSF at RT for 1 h to
guarantee the functional and energetic recovery. Slices were
incubated for 3 h at RT with continuously oxygenated aCSF
with 50 nM KTP-NH2 in the presence or absence of 200
nM Abolig.
Ex Vivo Electrophysiological Recordings
Long-term potentiation (LTP) induction and quantification were
performed as described previously (Diógenes et al., 2011). Briefly,
hippocampal slices were transferred to a recording chamber
continuously superfused with oxygenated aCSF at 32°C (flow
rate of 3 ml/min). Stimulation pulses were delivered every 20 s
using a bipolar concentric wire electrode placed on Shaffer
collateral/commissural fibers in stratum radiatum, and field-
excitatory post-synaptic potentials (fEPSPs) were recorded
extracellularly through a microelectrode filled with aCSF (2–6
MW) placed in the stratum radiatum of the CA1 area. The
intensity of stimulation was initially adjusted to obtain a fEPSP
slope with a minimal spike contamination and of around 50% of
the maximal slope. Recordings were obtained with an Axoclamp
2B amplifier (Axon Instruments, Foster City, CA, United States),
digitized, and continuously stored on a personal computer with
the WinLTP software (Anderson and Collingridge, 2001).
Individual responses were monitored, averages of six consecutive
responses were obtained, and the slope of the initial phase of the
fEPSP was quantified. After fEPSPs stabilization, LTP was induced
through a q-burst protocol (3 trains of 100 Hz, 3 stimuli, separated
by 200 ms). The q-burst induced LTP pattern of stimulation is
considered closer to what physiologically occurs in hippocampi
during episodes of learning and memory in living animals
(Albensi et al., 2007). We used a mild LTP protocol since this
proved to be sensitive to synaptic plasticity changes along withFrontiers in Pharmacology | www.frontiersin.org 6aging (Diógenes et al., 2011), and allows assessing both further
improvements or impairments on LTP magnitude. LTP
magnitude was quantified as the percentage of change in the
average slope of fEPSPs taken between 50 to 60 min after LTP
induction in relation to the average slope of fEPSPs measured
during the 10 min before q-burst induced LTP (baseline).
Primary Neuronal Cultures and
Drug Treatment
Primary neuronal cultures were obtained from fetuses of 18/19-
days pregnant Sprague-Dawley females, as routinely in the lab
(Jerónimo-Santos et al., 2015). Briefly, animals were deeply
anaesthetised with isoflurane and decapitated. The fetuses were
collected and placed in cold Ca2+- and Mg2+-free Hank’s
Balanced Salt Solution (HBSS) (Gibco, Paisley, UK). The
brains were dissected, the cerebral cortices were isolated, and
the meninges were removed. Then, the tissue was mechanically
fragmented, followed by enzymatic digestion with 0.025% (w/v)
of trypsin solution in HBSS for 15 min at 37°C. To neutralize the
action of trypsin, HBSS supplemented with FBS 20% (w/v) and
cellular suspension was centrifuged at 190g. The supernatant was
discarded, and the cells were resuspended in the same solution by
pipette aspiration in order to dissociate cells. This process was
repeated three times. After washing, cells were resuspended in
supplemented Neurobasal medium (0.5 mM L-glutamine, 25
mM glutamic acid, 2% B-27, and 25 U/ml penicillin/
streptomycin). Then, cell suspension was filtered (BD Falcon
Cell Strainer 70 mM, Thermo Fisher Scientific, Waltham, MA,
United States) to obtain single cells, and cell density was
determined by counting cells in a 0.4% trypan blue solution
using a hemocytometer. Cells were plated at 1 × 10−5 cells/well
on 12-wells flat-bottom cell plates covered with glass coverslips
(Corning® Costar® TC-treated, Sigma), and maintained at 37°C
in a humidified atmosphere of 95/5% O2/CO2, for 14 days. The
coverslips were previously sterilized under UV light, coated
overnight with 10 mg/ml of poly-D-lysine (Sigma, St. Louis,
MO, United States) and washed with sterile H2O. After 13
days in vitro (DIV13), cells were incubated with 50 nM KTP-
NH2 in the presence or absence of 25 µM Ab25–35, during 24 h.
Immunocytochemistry
In order to evaluate the neuroprotective effect of drug treatment,
spine density was counted as previously done in our lab
(Tanqueiro et al., 2018). Briefly, primary neuronal cultures at
DIV14 were fixed in 4% PFA in PBS (pH 7.4) for 15 min at RT,
after being washed with PBS twice. Using a blocking solution (3%
(w/v) BSA) (Sigma-Aldrich) in PBS with 0.1% (v/v) Triton X-
100, cells were incubated for 1 h at RT. To specifically detect
neurons, cells were incubated with mouse microtubule-
associated protein 2 (MAP2) primary antibody (1:200 in
blocking solution) (Millipore), overnight at 4°C in a wet-
chamber. After this, cells were washed with PBS twice and
then co-incubated in blocking solution with goat anti-mouse-
Alexa Fluor 568 secondary antibody (1:200, Invitrogen), Alexa
Fluor 488 Phalloidin (1:40) (Invitrogen), which recognizes
filamentous actin (F-actin), and Hoechst 33342 (6 µg/ml) forJuly 2020 | Volume 11 | Article 985
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being washed with PBS twice, coverslips were mounted in
Mowiol mounting solution. Using a confocal laser point-
scanning microscope LSM 880 with Airyscan (Carl Zeiss
MicroImaging, Thornwood, NY, United States), the
observed conjugation between MAP2 (568, red) and F-actin
(488, green) allowed the clear identification of dendritic
protrusions, since F-actin has an important role in the
constitution of the cytoskeleton of dendritic spines (Koskinen
and Hotulainen, 2014). Spine density was assessed as the number
of protrusions, counted per 10 µm of the parent dendrite, as
previously reported (Alonso et al., 2004; Ji et al., 2010) with a
distance of 25 µm from the cell body. Independent averages were
computed with counts of 3 different dendrites of each neuron, 6
neurons per condition, with each primary neuronal culture being
considered an independent experiment.
Statistical Analysis
Data are expressed as mean ± standard error of themean (mean ±
SEM), where n is the number of independent experiments. Results
of each animal per group, and results acquired from different
hippocampal slices of different animals were considered
independent experiments. The data normality was confirmed
using the Shapiro-Wilk test. Results obtained using behavioral
paradigms, OFT, YM-SAT, NORT (object recognition index and
object discrimination index), through electrophysiological
recordings (LTP magnitude), and using immunocytochemistry
(number of dendritic protrusions) were analyzed using two-way
ANOVA, followed by the Tukey’s multiple comparisons test. In
addition, significant differences between means of NORT object
preference index within each phase were evaluated through
unpaired two-tailed Student’s t-test. Results obtained by
Western blot (WB) were analyzed using two-way ANOVA.
Values of p < 0.05 were considered to represent statistically
significant differences. All statistical analyses were conducted
using the Prism Software (GraphPad Prism®, version 8.0.2,
California, USA).RESULTS
KTP-NH2 Treatment Prevented Episodic
Long-Term and Spatial Working Memory
Dysfunction Induced by Ab
To evaluate the influence of KTP-NH2 in an animal model of AD
(Canas et al., 2009; Zhang et al., 2015), KTP-NH2 (32.3 mg/kg) or
saline solution (vehicle) was i.p. administered for 18 days to rats
that had received a 5 µl i.c.v injection of Ab1–42 (2.25 mg/ml) or
water (vehicle) (Figure 1A). As such, the experimental groups
are the following: control group (vehicles); KTP-NH2 group
(vehicle + KTP-NH2 treatment); Ab group (Ab and vehicle
treatment); and Ab + KTP-NH2 group (Ab and KTP-NH2
treatment) (Figure 1B).
Episodic long-term memory, considered the predominant
cognitive deficit in AD, was evaluated through the NORT with
a retention time of 24 h (see Methods). As expected, in theFrontiers in Pharmacology | www.frontiersin.org 7training phase (Figure 2, gray bars), the four groups of animals
explored approximately the same amount of time the two
identical objects. In the test day (Figure 2, black and white
bars), animals from the Ab group did not react to novelty (p >
0.05, unpaired two-tailed Student’s t-test to compare % of time
spent with familiar vs. novel object; n = 6; Figure 2C), whereas
the control group did (p ≤ 0.0001, unpaired Student’s t-test to
compare % of time spent with familiar vs. novel object; n = 7;
Figure 2A). Remarkably, the Ab induced-impairment in the
NORT was totally recovered in the animals that had been treated
with KTP-NH2 (Figure 2D). These treated animals showed a
clear preference for exploring the novel object more than the
familiar one (p ≤ 0.0001, unpaired Student’s t-test to compare %
of time spent with familiar vs. novel object; n = 6), thus behaving
like control animals. The KTP-NH2 group also behaved like a
control group (p > 0.05, unpaired two-tailed Student’s t-test to
compare % of time spent with familiar vs. novel object; n = 7;
Figure 2B), indicating that per se KTP-NH2, is not a memory
enhancer, though markedly ameliorating memory deficits
elicited by Ab.
To better compare performances among the four groups of
animals, the time spent exploring each object in the test day was
converted into the object recognition index [novel/(novel +
familiar)], and the object discrimination index [(novel –
familiar)/(novel + familiar)], which were calculated for each
animal and averaged within each group (Figures 3A, B,
respectively). The object recognition index ranges from 0 to 1,
where obtained values around 0.5 reflect an absence of
discrimination between the novel and the familiar objects. The
discrimination index ranges from −1 to +1, and obtained values
around 0 reflect lack of object discrimination. In both indexes,
higher obtained values indicate higher memory performance. As
depicted in Figure 3, the recognition index attained by the Ab
group was significantly different from the control group (Ab:
0.48 ± 0.046 vs. control: 0.71 ± 0.028; p < 0.05, two-way ANOVA
with Tukey’s multiple comparisons test; n = 6–7). Importantly,
the index displayed by the Ab + KTP-NH2 group, (0.67 ± 0.020,
n = 6) was similar to the control group (p > 0.05, two-way
ANOVA with Tukey’s multiple comparisons test; n = 6–7), and
significantly different from Ab group (p < 0.05, two-way
ANOVA with Tukey’s multiple comparisons test; n = 6–7).
Moreover, the KTP-NH2 treatment alone (KTP-NH2 group)
did not affect the object recognition index (0.68 ± 0.028, n = 7)
when compared to the control group (p > 0.05, two-way
ANOVA with Tukey’s multiple comparisons test; n = 6–7).
Thus, this analysis further confirms that KTP-NH2 treatment
had beneficial effects on the performance of Ab i.c.v. injected
animals in long-term memory testing. Similar findings were
obtained by calculated scores of the discrimination index
(control: 0.43 ± 0.058; Ab: −0.05 ± 0.091; KTP-NH2: 0.36 ±
0.053; and Ab + KTP-NH2: 0.35 ± 0.039, two-way ANOVA with
Tukey’s multiple comparisons test; n = 6–7).
To determine whether KTP-NH2 treatment could counteract the
Ab induced-impairments in spatial working memory, animals were
subjected to the YM-SAT, and their performance was assessed
through the percentage of spontaneous alternation as described inJuly 2020 | Volume 11 | Article 985
Belo et al. Neuroprotective Action of Amidated-Kyotorphinmethods (Figure 3B). As expected, animals from Ab group had a
lower percentage of spontaneous alternation when compared with
animals from the control group (Ab: 55 ± 3.5 vs. control: 69 ± 2.0,
p < 0.05, two-way ANOVAwith Tukey’s multiple comparisons test;
n = 6–7), confirming that Ab i.c.v. injected animals had an
impairment in spatial working memory. However, when Ab i.c.v.
injected animals were treated with KTP-NH2 (Ab + KTP-NH2
group) the percentage of spontaneous alternation in the YM-SATFrontiers in Pharmacology | www.frontiersin.org 8(67 ± 1.3, n = 6) was similar to the control group (p > 0.05, two-way
ANOVA with Tukey’s multiple comparisons test; n = 6–7), and
significantly different from that of the Ab group (p < 0.05, two-way
ANOVA with Tukey’s multiple comparisons test; n = 6–7),
implying that KTP-NH2 treatment reduced the Ab induced-
deficits in YM-SAT. Moreover, KTP-NH2 alone had no
significant effect, since the percentage of spontaneous alternation
of animals from KTP-NH2 group (68 ± 2.4, n = 7) was notA B C
FIGURE 3 | KTP-NH2 treatment mitigates Ab-induced impairments in long-term episodic memory and spatial working memory. (A) Object recognition index was
calculated from the data obtained in the test day of the Novel Object Recognition test (NORT), as [novel / (novel + familiar)], and it ranges from 0 to 1 (where 1
means only exploration of the novel object and zero means only exploration of the familiar object). (B) Object discrimination index was also calculated from the data
obtained in the test day of NORT, as [(novel – familiar) / (novel + familiar)], and it ranges from −1 to 1, where zero means no discrimination between both objects. (C)
The percentage of spontaneous alternation was calculated from data obtained during the Y-Maze Spontaneous Alternation test (YM-SAT), as actual alternations/
maximum alternations x 100. For each statistical analysis, significant differences between the group of Ab animals (n = 6) and all the other groups (n = 6–7) were
assessed using two-way ANOVA followed by Tukey’s multiple comparisons test. *p < 0.05, **p ≤ 0.01, ***p ≤ 0.001. Data are represented as mean ± SEM.A B
C D
FIGURE 2 | The KTP-NH2 treatment mitigates Ab-induced impairments in long-term (24 h) episodic memory. Long-term episodic memory was evaluated through
the Novel Object Recognition test (NORT). After 3 arena habituation sessions, the training phase consisted of one session with two identical objects (F1 and F2)
placed inside the arena. The test phase occurred on the following day (24 h later), where one of the familiar objects (Familiar) was replaced by a novel object (Novel).
During both phases, animals freely explore the objects for 5 min and the results are given by the time spent exploring any one of the two objects allows to calculate
the Object Preference Index, i.e., F1 or F2 / (F1 + F2) and Familiar or Novel / (Familiar + Novel). A preference index above 0.5 indicates a preference of that specific
object, whereas equal to 0.5 represents no preference. Statistical analysis using unpaired two-tailed Student’s t-test showed no statistical differences in preference
between objects during the training phase (as expected), and revealed a significant preference for the novel objects during the test phase for control (A), KTP-NH2
(B), and Ab + KTP-NH2 (D) groups (n = 6–7), which indicates that memory is conserved within these animals. For the Ab group (C), data showed that there was no
preference between familiar and novel objects (n = 6). ****p ≤ 0.0001. Data are represented as mean ± SEM.July 2020 | Volume 11 | Article 985
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ANOVA with Tukey’s multiple comparisons test).
Performance in the NORT and in the YM-SAT can be
affected by changes in locomotion, by anxiety-like behavior, or
by alterations in exploratory drive. To control for these
parameters, animals were assessed in the OFT. No statistically
significant differences (Figure 4; p > 0.05, two-way ANOVA; n =
6–7) were found between any of the experimental groups when
analyzing the total distance travelled (Figure 4A), or the average
velocity (Figure 4B). In addition, the total number of entries in
the YM-SAT arms was also analyzed (control: 26 ± 1.6; Ab: 23 ±Frontiers in Pharmacology | www.frontiersin.org 91.5; KTP-NH2: 25 ± 2.0; Ab + KTP-NH2: 21 ± 1.5), and no
significant differences were found between any of the groups (p >
0.05, two-way ANOVA; n = 6–7). Together, these results show
that neither Ab, nor KTP-NH2, alone or in combination, caused
appreciable effects in locomotor activity that could mask
performance in the NORT or YM-SAT. Similarly, no
statistically significant differences (p > 0.05, two-way ANOVA,
n = 6–7) were found between groups for the percentage of time
spent in the periphery of the OFT arena (Figure 4C), which also
indicates an absence of appreciable changes in anxiety-
like behaviour.
Hippocampal Gliosis Immediately After
Testing Was Not Different Among the
Groups
To assess if Ab could lead to an increase in the proliferation of
astrocytes and microglia at the time of testing, which could
suggest gliosis and thus inflammation, WB assays were
performed with protein extracts obtained from hippocampal
homogenates prepared upon animal sacrifice after behavioral
testing. GFAP and Iba-1 were used as markers for astrocytes and
microglia, respectively (Figure 5). Densitometry analyses of the
WB revealed no significant changes (n=3–4; p > 0.05, two-way
ANOVA) in samples from Ab injected animals when compared
with control, and in response to KTP-NH2 treatment, thus
indicating an absence of proliferation of astrocytes and
microglia cells. Nevertheless, since WB assay did not provide
information about morphological changes of astrocytes and
microglia, immunohistochemistry analysis of glial cell
morphology was performed to further address this issue. As
shown in Figure 6, regardless of the hippocampal area analyzed
(CA1 or DG), there was no evidence of astrogliosis (evaluated by
GFAP immunoreactivity) or microgliosis (evaluated by Iba-1
immunoreactivity), either in control or Ab animals, treated or
untreated with KTP-NH2, since no morphologic differences in
glial cells were noticeable.
KTP-NH2 Prevented the Impairment in q-
Burst-Induced LTP Magnitude Caused by
Ab
To address the synaptic mechanisms involved in the ability of
KTP-NH2 to mitigate memory impairment in animals injected
with Ab, we assessed the effect of KTP-NH2 upon q-burst-
induced LTP in hippocampal slices that had been incubated
with 200 nM Abolig (Figures 7A, B), a known to be toxic
conformational arrangement of Ab (Giuffrida et al., 2009).
LTP magnitude (Figure 7C), recorded in slices pre-incubated
with 200 nMAbolig for 3 h (Ab) was significantly decreased when
compared to that attained in control slices incubated for a similar
amount of time in the absence of Ab (control: 25.4 ± 6.15 vs.
Ab: −4.52 ± 6.53, p < 0.05, two-way ANOVA with Tukey’s
multiple comparisons test; n = 5–8). Remarkable, in slices co-
incubated with 200 nM Abolig and 50 nM KTP-NH2 (Ab + KTP-
NH2), LTP magnitude (24.2 ± 3.50, n = 5) attained values similar
to those in control slices (p > 0.05, two-way ANOVA with
Tukey’s multiple comparisons test; n = 5–8). Moreover, LTPA
B
C
FIGURE 4 | Neither Ab nor KTP-NH2 treatment affected locomotor activity or
anxiety-like behaviour. Results obtained during the Open-field test (OFT)
performance allow the assessment of locomotor activity through the (A) total
distance travelled (cm), and (B) average velocity (cm/s). (C) Anxiety-like
behaviour was evaluated through the percentage of time spent in the
periphery of the OFT. Statistical analysis using two-way ANOVA did not reveal
significant differences (p < 0.05) between groups (n = 6-7). Data are
represented as mean ± SEM.July 2020 | Volume 11 | Article 985
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FIGURE 5 | Neither Ab nor KTP-NH2 affected hippocampal gliosis assessed by immunoblotting. Protein levels were assessed by western blotting using tissue
homogenates from each isolated hippocampus of 13 animals, 3-4 for each experimental group (Control, KTP-NH2, Ab, and Ab + KTP-NH2). (A) Representative
immunoblots of GFAP (50 kDa), Iba-1 (17 kDa) and GAPDH (37 kDa). GAPDH was used as a loading control. (B) Densitometry analysis of the right (R) (side of i.c.v
injection) hippocampus, performed for all groups with ImageJ software. No statistically significant differences were found between animal groups regarding GFAP or
Iba-1 immunoreactivity and (p > 0.05, two-way ANOVA, n = 3-4). Data are represented as mean ± SEM.FIGURE 6 | Neither Ab nor KTP-NH2 affected hippocampal gliosis assessed by immunohistochemistry labeling. At day 21, thirteen deeply anesthetized animals
were transcardially perfused with ice-cold saline and 4% PFA solutions. After decapitation, brains were removed and gelatin-embedded to be sectioned on a
cryostat. Coronal sections located at hippocampus level were collected and mounted for labelling with GFAP to stain astrocytes (red) and Iba-1 to stain microglia
(green). Nuclei were stained with Hoechst (blue). Images of both CA1 and DG hippocampal areas were acquired on an inverted wide-field fluorescence microscope
(Zeiss Axiovert 200), with a 40x objective. The figure includes representative images of each experimental group (Control, KTP-NH2, Ab, and Ab + KTP-NH2). There
was no difference in GFAP or Iba-1 staining between conditions. Scale bar, 50 µm.Frontiers in Pharmacology | www.frontiersin.org July 2020 | Volume 11 | Article 98510
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(KTP-NH2) was similar (27.0 ± 8.10, n = 4) to that in control
slices (p > 0.05, two-way ANOVA with Tukey’s multiple
comparisons test; n = 5–8). Altogether, these results clearly
indicate that KTP-NH2 prevents Ab-induced impairment of
LTP without by itself affecting LTP.
KTP-NH2 Prevented the Decrease in Spine
Density Caused by Ab Action on Cultured
Cortical Neurons
To further investigate the synaptic correlates of the protective
action of KTP-NH2 against Ab-induced synaptic impairment, we
evaluated the effect of KTP-NH2 on spine density of cultured
cortical neurons. The conjugation between MAP2 (red) and
Phalloidin (green) labels, allowed the identification of dendritic
protrusions (yellow) (Figure 8A), as a morphological readout of
the treatment modulation of the number of dendritic spines. The
representative segments of 10 µm of counted dendrites for each
analysed condition are illustrated in Figure 8B.
In accordance with previous studies (Tanqueiro et al., 2018),
cultured cortical neurons exposed to Ab25–35 for 24 h, showed a
significant decrease in the number of dendritic protrusions when
compared to the control condition (Ab: 6.58 ± 0.153 vs. control:
8.07 ± 0.153; p < 0.05, two-way ANOVA with Tukey’s multiple
comparisons test; n = 5) (Figure 8C). Remarkably, the Ab-induced
impairment in the number of dendritic protrusions was absent
when neurons were co-treated with 50 nM KTP-NH2 (Ab + KTP-
NH2: 9.60 ± 0.134 vs. control: 8.07 ± 0.153; p < 0.05, two-way
ANOVA with Tukey’s multiple comparisons test; n = 5). KTP-NH2Frontiers in Pharmacology | www.frontiersin.org 11alone did not significantly alter dendritic protrusions when
compared to the control condition (KTP-NH2: 8.41 ± 0.071 vs.
control: 8.07 ± 0.153; p > 0.05, two-way ANOVA with Tukey’s
multiple comparisons test; n = 5).DISCUSSION
A main finding in the present work is that systemically applied
KTP-NH2 prevents memory dysfunction induced by Ab. At the
synaptic level we could demonstrate that KTP-NH2 prevents
synaptic plasticity and spine density impairments caused by Ab,
suggesting that KTP-NH2 mitigates memory deficits by
protecting hippocampal synapses against Ab-induced toxicity.
Since the hippocampus is required for performance in the
NORT (Goulart et al., 2010), this test has been considered a
useful tool for basic and preclinical research in the context of AD
(Rajagopal et al., 2014). In addition, the sustained strengthening
of synaptic connections that characterizes hippocampal long-
term potentiation (LTP) is taken as a synaptic correlate of the
basic mechanisms involved in memory and learning processes
(Bliss and Collingridge, 1993). Accordingly, abnormal
performance in memory tasks, especially hippocampal-
dependent ones (Figurov et al., 1996; Korte et al., 1998; Pang
and Lu, 2004), are associated with impairments in LTP (Morris
et al., 1986). Our data showing that KTP-NH2 prevented the Ab-
induced impairment of hippocampal LTP, strongly suggest that
the reestablishment of synaptic plasticity is one of the
mechanisms underlying the cognitive actions of KTP-NH2.A B
C
FIGURE 7 | Incubation with KTP-NH2 reduces the impact of Ab on LTP magnitude upon q-burst-induced LTP. (A) The averaged time courses changes in field
excitatory post-synaptic potential (fEPSP) slope (% baseline) induced by a q-burst stimulation in animal hippocampal slices with a pre-exposure of 3 h to aCSF
solution (control, n = 8) with 200 nM Abolig (Ab, n = 5), 50 nM KTP-NH2 (KTP-NH2, n = 4), or 200 nM Abolig and 50 nM KTP-NH2 (Ab + KTP-NH2, n = 5). (B)
Tracings from representative experiments. For each condition, fEPSP tracings recorded at baseline (baseline, grey line) and after q-burst-induced LTP (LTP, black
line) from the same slice are showing overlaid. (C) Histogram depicting the effect on LTP magnitude (% average changes in fEPSP slope at 50-60 min normalized to
the defined baseline of 10 min immediately before q-burst stimulation) regarding each group under study (control, Ab, KTP-NH2, Ab + KTP-NH2). Statistical analysis
using two-way ANOVA followed by Tukey’s multiple comparisons test indicates a significant difference between the Ab condition (n = 5), and all the other groups
(n = 4-8). *p < 0.05. Data are represented as mean ± SEM.July 2020 | Volume 11 | Article 985
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been associated with synaptic reinforcement during LTP (Toni
et al., 1999; Luscher and Malenka, 2012). In fact, spine density is
known to be reduced in cultured cortical neurons incubated with
Ab peptide (Tanqueiro et al., 2018). Our results show that KTP-
NH2 restores Ab-induced decrease in spine density, further
explaining its neuroprotective actions upon synaptic plasticity.
These results pave the way for further studies on the mechanism
of action of KTP-NH2 addressing if it reestablishes spine density
in vivo.
While the presence of episodic memory impairments mimics
the clinical hallmarks detected in AD patients in the early stages
of the disease (Alescio-Lautier et al., 2007; Gold and Budson,
2008; Huntley and Howard, 2010), motor dysfunctions are
better noticed in moderate to severe stages of AD (Zidan
et al., 2012). In the present work, we could detect episodic
memory dysfunctions through the YM-SAT and NORT,
without signs of clear motor dysfunctions, judged by OFTFrontiers in Pharmacology | www.frontiersin.org 12performance. This indicates that the sporadic AD model used
mostly mimics the earlier stages of AD. It is known that loss of
synapses, mainly in the hippocampus, is one of the earliest
consequences of Ab toxicity (Canas et al., 2009), and that this
loss correlates with the initial memory impairments in AD
patients (Coleman et al., 2004). Furthermore, compared to the
transgenic models of AD available, the use of this sporadic AD
model, where the Ab injection is responsible for the induced-
pathophysiological traits of AD, allows us to have a direct
understanding of the effect of KTP-NH2 administration on the
Ab-induced dysfunction. Our findings support that systemic
administration of KTP-NH2 is able to prevent memory loss as
well as synaptic plasticity dysfunctions induced by Ab, highlight
the therapeutic potential of BBB permeable KTP analogues in
early stages of AD. This may gain particular relevance since the
few therapeutic tools so far available for early disease stages are
mostly symptomatic to increase cholinergic function. As we
show, the KTP derivative is able to enhance synaptic plasticityA
B C
FIGURE 8 | Incubation with KTP-NH2 mitigates Ab incubation-induced impairments in spine. (A) Representative image of an untreated neuron (control) obtained
from primary neuronal cultures. Primary neuronal cultures (DIV13) were incubated with 25 µM Ab25-35 and/or with 50 nM KTP-NH2 for 24 h. MAP2 (red) specifically
labels neurons, while phalloidin (green) labels F-actin. The merge between both labels (yellow) allows the identification of dendritic protrusions. To evaluate spine
density, the number of protrusions per 10 µm of the parent dendrite with a distance of 25 µm from the cell body were counted (3 parent dendrites per neuron, 6
neurons per condition). (B) Treatment effects on synaptic density (10 µm). (C) Histogram depicting spine density as the number of protrusions from each condition.
Statistical analysis using two-way ANOVA followed by Tukey’s multiple comparisons test indicates a significant difference between conditions (n = 5). While 25 µM
Ab25-35 treatment (Ab) diminished the number of protrusions in cortical neurons, 50 nM KTP-NH2 co-treatment (Ab + KTP-NH2) restored spine density. In addition,
50 nM KTP-NH2 treatment (KTP-NH2) did not, by itself, impact spine density. ****p ≤ 0.0001. Data are represented as mean ± SEM.July 2020 | Volume 11 | Article 985
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cultured neurons, thus to prevent synaptic atrophy, a clear sign
of neuroprotective ability.
Furthermore, KTP biosynthesis occurs in the nerve terminals
(Ueda et al., 1986), which is especially relevant in AD
pathophysiology, where the loss of cortical mass evolves fast
during the early stages of the disease (Sabuncu, 2011). This
cellular death implies less KTP production capability, resulting in
a decrease of KTP concentration in the CSF of AD patients
(Santos et al., 2013). Accordingly, the increase of KTP levels in
the brain emerged as a possible therapeutic tool for AD
treatment. However, KTP has pharmacokinetic hindrances,
such as its limited capacity to cross the BBB and its high
susceptibility to clearance mechanisms, which hampered its
clinical use (Serrano et al., 2015). Our work shows that it is
possible to circumvent this problem by using a BBB permeant
KTP analogue, KTP-NH2. The introduced structural change
increased the peptide global net charge, increasing its capacity
to interact with biological membranes, most notably giving it the
ability to cross the BBB (Ribeiro et al., 2011a).
Besides having an acute and chronic well-characterized
analgesic-profile when systemically administrated (Ribeiro
et al., 2011a; Ribeiro et al., 2011b), this small and cost-effective
molecule also showed a remarkable anti-inflammatory effect.
Accordingly, independent studies developed by our lab showed
that KTP-NH2 impacts the glucocorticoid system, which might
account for the molecular link between analgesia, anti-
inflammation, and neuroprotection (Perazzo et al., 2017).
Neuroinflammation caused by Ab has been commonly linked
to the presence of gliosis and, in some studies, to neuronal
damage. In the present work, gliosis was evaluated on day 21
after Ab i.c.v. injection by both immunohistochemistry and
Western blotting and, in agreement with previous data (Canas
et al., 2009), no significant signs of astrogliosis nor microgliosis
were detected in the hippocampus. However, it is important to
highlight that the peak of the inflammatory response after Ab
injection is one week after injection (McLarnon, 2014). So, we
cannot discard initial Ab-induced neuroinflammation nor an
influence of KTP-NH2 that may have occurred before memory
assessment. Nevertheless, our results show that at least
immediately after memory testing, there were no signs of gliosis.
In summary, we clearly show that, in a sporadic AD model,
systemic administration of KTP-NH2 protects spatial working-
and episodic memory, without affecting motor activity or
inducing anxiety-like behavior. Moreover, KTP-NH2 prevented
Ab-induced deficits in LTP magnitude and in spine density. We,
therefore, highlight a neuroprotective action of KTP-NH2 against
the early stages of AD pathophysiology. While these results are
promising as far as pharmacodynamics is concerned, they clearly
push toward the need of further studies on the pharmacokinetics
of KTP-NH2 after its systemic administration through different
routes, as well as to the need of other studies directed toward
other hallmarks of AD. Indeed, in light of the complex
pathophysiology of AD, it is important to know whether KTP-
NH2 has a greater potential as a standalone treatment, or rather
as part of a broader multidrug treatment regimen.Frontiers in Pharmacology | www.frontiersin.org 13DATA AVAILABILITY STATEMENT
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